Autoimmune Diseases  >>  Lispro-PH20 (insulin lispro/rHuPH20)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lispro-PH20 (insulin lispro/rHuPH20) / Halozyme
NCT00883558: Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Checkmark P2 data- EASD
Jul 2012 - Jul 2012: P2 data- EASD
Completed
2
48
US
Insulin Lispro, Humalog, regular human insulin, Humulin R, recombinant human hyaluronidase PH20, Hylenex, rHuPH20, PH20, Insulin glargine, Lantus
Halozyme Therapeutics
Diabetes Mellitus, Type 1
02/10
04/10
NCT01194245: Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Completed
2
135
US
Insulin lispro, Humalog, recombinant human hyaluronidase PH20, Hylenex, rHuPH20, PH20, Insulin aspart, Insulin glulisine, Apidra, Insulin glargine, Lantus
Halozyme Therapeutics
Diabetes Mellitus, Type 1
08/11
08/11

Download Options